Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IRL752 in Parkinson's Disease Dementia (Phase IIa, randomized, double-blind, placebo-controlled)
2017-001673-17Phase 2Completed
- Sponsor
- IRLAB
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease dementia (PDD) comparing IRL752 with Placebo (2 arms). Primary endpoint: Safety and tolerability of IRL752 after repeated dosing. Started Jul 2017; status: completed.
02
Drugs
Pirepemat
03
Conditions
Parkinson's disease dementia (PDD)
Beyond the preview
Go deeper on 2017-001673-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001673-17.